title: Impact of baseline body mass index status on glucose lowering and weight change during sitagliptin treatment for type 2 diabetics.
abstract: OBJECTIVE
  This study was designed to evaluate the efficacy of sitagliptin in Taiwanese diabetic subjects with different baseline BMI status.
  
  
  METHODS
  This was a single-center, hospital-based, retrospective chart review in subjects (n=1874) with type 2 diabetes who received sitagliptin. Subjects were classified into subgroups depending upon their baseline BMI by Taiwan national weight classification: normal (BMI<24kg/m(2)) (n=504), overweight (BMI: 24-27kg/m(2)) (n=615), and obese (BMI⩾27kg/m(2)) (n=755). Changes in HbA1c and weight were evaluated over a 12month treatment period.
  
  
  RESULTS
  For all three groups, the HbA1c levels declined over the first three months by about 8%, and subsequently plateaued for the next nine months. Obese subjects were slower in reducing HbA1c compared with normal and overweight subjects (P<0.05), but at nine months the reduction was similar across groups. Mean body weight increased over the first nine months of sitagliptin therapy in subjects with normal BMI (57.12-58.30kg), but there was no change in mean body weight in the overweight group. After three months the obese groups had significantly greater loss in body weight compared with the normal group.
  
  
  CONCLUSIONS
  Baseline BMI status may influence the reduction of HbA1c levels within the first six months of sitagliptin therapy and affect weight change after three months. Being obese was associated with an initial lag in HbA1c reduction and greater weight loss compared with normal and overweight subjects.
authors: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 123, Ta-Pei Road, Niao-Sung District, Kaohsiung City, Taiwan, ROC.
authors: Jung-Fu
authors: JF
authors: Chen
authors: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 123, Ta-Pei Road, Niao-Sung District, Kaohsiung City, Taiwan, ROC.
authors: Chih-Min
authors: CM
authors: Chang
authors: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 123, Ta-Pei Road, Niao-Sung District, Kaohsiung City, Taiwan, ROC.
authors: Ming-Chun
authors: MC
authors: Kuo
authors: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 123, Ta-Pei Road, Niao-Sung District, Kaohsiung City, Taiwan, ROC.
authors: Shih-Chen
authors: SC
authors: Tung
authors: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 123, Ta-Pei Road, Niao-Sung District, Kaohsiung City, Taiwan, ROC.
authors: Cheng-Feng
authors: CF
authors: Tsao
authors: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 123, Ta-Pei Road, Niao-Sung District, Kaohsiung City, Taiwan, ROC. Electronic address: lkmann@adm.cgmh.org.tw.
authors: Chia-Jen
authors: CJ
authors: Tsai
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D050177:Overweight / Q000150:complications; D012189:Retrospective Studies; D000068900:Sitagliptin Phosphate / Q000627:therapeutic use*; D013624:Taiwan
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000068900:Sitagliptin Phosphate
keywords: Body mass index; HbA1c; Obesity; Sitagliptin; Type 2 diabetes